Michael E. Beil

TL;DR: FAD is a potent, orally active, and relatively selective ASI in two rat models of hyperaldosteronism and metyrapone is an order of magnitude less selective than FAD but is, nevertheless, more potent as an ASI than as an 11β-hydroxylase inhibitor.

TL;DR: Compound 7n was found to be a potent inhibitor of 11β-hydroxylase (CYP11B1), which is responsible for cortisol production, and is being evaluated in the clinic for potential treatment of hypercortisol diseases such as Cushing's syndrome.

TL;DR: These results provide new insights into the cardiac and renal effects of inhibiting aldosterone synthase in experimental models and translation of the hormonal effects to humans.

TL;DR: The present investigation aims to extend the previously developed model by parsing CO into heart rate (HR) and stroke volume (SV) and evaluate if the mechanism of action (MoA) of new compounds can be elucidated using only HR and MAP measurements.

TL;DR: Findings suggest that opiate-like substances possibly released by the ischemic myocardium do not contribute significantly to the etiology of cardiac arrhythmias, or sudden death associated with the early stages of myocardial infarction in pigs.